Ioversol (MP-328) |
| رقم الكتالوجGC30133 |
Ioversol (MP-328) (MP-328) هو وسيط تباين غير أيوني معالج باليود (CM) يُستخدم أثناء التصوير المقطعي المحوسب أو الأشعة السينية في التجارب على الحيوانات.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 87771-40-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ioversol is a nonionic iodinated contrast agent.
Ioversol (100 mg iodine/ml) exposure induces significantly increased lactate dehydrogenase release and decreased 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl tetrazolium bromide conversion in NRK-52E cells. Ioversol significantly increases apoptosis and caspase-3 protein expression in the NRK-52E cells exposed to ioversol for 4 h. Ioversol treatment induces a significant increase in [Ca2+]i and intracellular ROS[1].
In comparison with iothalamate, ioversol has a greatly reduced propensity to stimulate the release of endothelin, from cultured cells and when injected into anesthetized rats. Ioversol produces less renal vasoconstriction than does iothalamate, in control and in USIC rats, and the development of radiocontrast nephropathy, assessed by creatinine clearance and morphologic damage to the renal medulla, is largely avoided[2].
[1]. Yang D, et al. Selective inhibition of the reverse mode of Na(+)/Ca(2+) exchanger attenuates contrast-induced cell injury. Am J Nephrol. 2013;37(3):264-73. doi: 10.1159/000348526. Epub 2013 Mar 13. [2]. Heyman SN, et al. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol. 1993 Apr;28(4):313-8.
Cell experiment: | Cell viability is assessed by using the MTT uptake assay. The conversion of MTT, a tetrazolium salt, into formazan depends on the activity of a group of mitochondrial dehydrogenases and, thus, is an indicator of cell metabolic activity. The color of MTT tetrazole salt is measured with a spectrophotometer at the wavelength of 570 nm. Briefly, fresh MTT solution (10 mg/mL in 1× PBS) isadded (1:20 volume of medium) after removing the medium and the cells are incubated for 1.5 h. The cells are lysed and purple formazan dissolved into the solution by overnight incubation with MTT lysis buffer. The results are expressed as the percentage of undamaged control cells, assuming the absorbance of control wells as 100%. |
References: [1]. Yang D, et al. Selective inhibition of the reverse mode of Na(+)/Ca(2+) exchanger attenuates contrast-induced cell injury. Am J Nephrol. 2013;37(3):264-73. doi: 10.1159/000348526. Epub 2013 Mar 13. | |
| Cas No. | 87771-40-2 | SDF | |
| Canonical SMILES | O=C(C1=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO | ||
| Formula | C18H24I3N3O9 | M.Wt | 807.11 |
| الذوبان | DMSO : ≥ 100 mg/mL (123.90 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.239 mL | 6.1949 mL | 12.3899 mL |
| 5 mM | 0.2478 mL | 1.239 mL | 2.478 mL |
| 10 mM | 0.1239 mL | 0.6195 mL | 1.239 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *